The EPO issued Publication EP4037702A1, a patent application for rapafucin derivative compounds and methods of use, filed by Johns Hopkins University and Rapafusyn Research and Development, Inc. The patent is classified under C07D 401/12 (heterocyclic compounds with nitrogen heteroatoms) and A61P 1/00 (drugs for gastrointestinal disorders). The designated states include all major European jurisdictions (DE, FR, GB, IT, ES, NL, etc.). Inventors include Hong, Ullman, Semple, Yamamoto, Kumar, Sadagopan, Schmitt, and Liu.

Patent publications do not create compliance obligations for third parties. Organizations developing similar compounds should review the patent claims to assess potential licensing requirements or design-around strategies. The publication date of March 25, 2026 establishes the priority date for the claimed chemical entities and methods.